Ferium Drug Interactions

Interactions of Iron (III) Hydroxide Polymaltose Complex (IPC) with tetracycline or aluminium hydroxide were investigated in three human studies. No significant reduction in the absorption of tetracycline was observed. The plasma tetracycline concentration did not fall below the minimum inhibitory concentration level necessary for bacteriostasis. Iron absorption from IPC was not reduced by aluminium hydroxide and tetracycline. IPC can therefore also be administered simultaneously with tetracyclines or other phenolic compounds and with aluminium hydroxide.
Studies in rats with tetracycline, aluminium hydroxide, acetylsalicylate, sulfasalazine, calcium carbonate, calcium acetate, calcium phosphate in combination with vitamin D3, bromazepam, magnesium aspartate, D-penicillamine, methyldopa, paracetamol and auranofin have not shown any interaction with iron (III) hydroxide polymaltose complex.
In addition, no interactions of iron (III) hydroxide polymaltose complex with food constituents such as phytic acid, oxalic acid, tannin, sodium alginate, choline and choline salts, vitamin A, vitamin D3 and vitamin E, soya oil and soya flour were observed in in vitro studies. These results suggest that iron hydroxide polymaltose complex can be taken during or immediately after food intake.
The hemoccult test (selective for Hb) for the detection of occult blood is not impaired; and therefore, there is no need to interrupt the therapy.
The simultaneous administration of parenteral iron preparations and iron hydroxide polymaltose complex is not indicated since it would reduce the absorption of the oral iron preparation.
Folic acid could increase phenytoin metabolism, leading to lower serum phenytoin concentrations, especially in folate deficient patients. Some patients may experience an increased frequency of epileptic seizures. Patients who take phenytoin or other antiepileptics/anticonvulsants should consult a doctor before taking a folic acid supplement.
There are reports that concomitant administration of chloramphenicol and folic acid in patients with folic acid deficiency may reduce the hematopoietic response to folic acid. Although the importance and mechanism of this interaction is unclear, the hematopoietic response to folic acid should be carefully monitored in patients receiving both medicines at the same time.